Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management

被引:1998
作者
Beckman, JA
Creager, MA
Libby, P
机构
[1] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Leducq Ctr Cardiovasc Res, Boston, MA USA
[2] Harvard Univ, Sch Med, Boston, MA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2002年 / 287卷 / 19期
关键词
D O I
10.1001/jama.287.19.2570
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Complications of atherosclerosis cause most morbidity and mortality in patients with diabetes mellitus. Despite the frequency and severity of disease, proven medical therapy remains incompletely understood and underused. Objective To review the epidemiology, pathophysiology, and medical and invasive treatment of atherosclerosis in patients with diabetes mellitus. Data Sources Using the index terms diabetes mellitus, myocardial infarction, peripheral vascular diseases, cerebrovascular accident, endothelium, vascular smooth muscle, platelets, thrombosis, cholesterol, hypertension, hyperglycemia, insulin, angioplasty, and coronary artery bypass, we searched the MEDLINE and EMBASE databases from 1976 to 2001, Additional data sources included bibliographies of identified articles and preliminary data presented at recent cardiology conferences. Study Selection We selected original investigations and reviews of the epidemiology, pathophysiology, and therapy of atherosclerosis in diabetes. We selected randomized, double-blind, controlled studies, when available, to support therapeutic recommendations. Criteria for data inclusion (168 of 396) included publication in a peer-reviewed journal or presentation at a national cardiovascular society-sponsored meeting. Data Extraction Data quality was determined by publication in peer-reviewed literature. Data extraction was performed by one of the authors. Data Synthesis Diabetes mellitus markedly increases the risk of myocardial infarction, stroke, amputation, and death. The metabolic abnormalities caused by diabetes induce vascular dysfunction that predisposes this patient population to atherosclerosis. Blood pressure control, lipid-lowenng therapy, angiotensin-converting enzyme inhibition, and antiplatelet drugs significantly reduce the risk of cardiovascular events, Although diabetic patients undergo revascularization procedures because of acute coronary syndromes or critical limb ischemia, the outcomes are less favorable than in nondiabetic cohorts. Conclusions Since most patients with diabetes die from complications of atherosclerosis, they should receive intensive preventive interventions proven to reduce their cardiovascular risk.
引用
收藏
页码:2570 / 2581
页数:12
相关论文
共 170 条
  • [111] Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)
    Pedersen, TR
    Kjekshus, J
    Pyörälä, K
    Olsson, AG
    Cook, TJ
    Musliner, TA
    Tobert, JA
    Haghfelt, T
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (03) : 333 - 335
  • [112] Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot
    Peters, EJG
    Lavery, LA
    [J]. DIABETES CARE, 2001, 24 (08) : 1442 - 1447
  • [113] Carotid endarterectomy in diabetic patients
    Pistolese, GR
    Appolloni, A
    Ronchey, S
    Martelli, E
    [J]. JOURNAL OF VASCULAR SURGERY, 2001, 33 (01) : 148 - 154
  • [114] Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.
    Plutzky J.
    [J]. Current Atherosclerosis Reports, 2000, 2 (4) : 327 - 335
  • [115] Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease - A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
    Pyorala, K
    Pedersen, TR
    Kjekshus, J
    Faergeman, O
    Olsson, AG
    Thorgeirsson, G
    [J]. DIABETES CARE, 1997, 20 (04) : 614 - 620
  • [116] Endothelin 1 transcription is controlled by nuclear factor-κB in AGE-stimulated cultured endothelial cells
    Quehenberger, P
    Bierhaus, A
    Fasching, P
    Muellner, C
    Klevesath, M
    Hong, M
    Stier, G
    Sattler, M
    Schleicher, E
    Speiser, W
    Nawroth, PP
    [J]. DIABETES, 2000, 49 (09) : 1561 - 1570
  • [117] RAMANATHAN AV, 1999, CIRCULATION S1, V100, P640
  • [118] INSULIN-RESISTANCE AND HYPERINSULINEMIA IN INDIVIDUALS WITH SMALL, DENSE, LOW-DENSITY-LIPOPROTEIN PARTICLES
    REAVEN, GM
    CHEN, YDI
    JEPPESEN, J
    MAHEUX, P
    KRAUSS, RM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01) : 141 - 146
  • [119] Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: The Health, Aging and Body Composition Study
    Resnick, HE
    Shorr, RI
    Kuller, L
    Franse, L
    Harris, TB
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (09) : 869 - 876
  • [120] Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with Non-ST-segment-elevation acute coronary syndromes
    Roffi, M
    Chew, DP
    Mukherjee, D
    Bhatt, DL
    White, JA
    Heeschen, C
    Hamm, CW
    Moliterno, DJ
    Califf, RA
    White, HD
    Kleiman, NS
    Theroux, P
    Topol, EJ
    [J]. CIRCULATION, 2001, 104 (23) : 2767 - 2771